EQVALAN® GOLD
EQVALAN® GOLD
Search
Our Global Support Program
Our global support programme
The wise choice in mastitis prevention
The wise choice in mastitis prevention
Online application
Online application | FAQ
Internal application
Internal applications | FAQ
Early Careers
Early Careers
Data Careers
Data Careers
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
COACH Program
The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.
Public-Health-Cost-from-AF
2021-Your-Guide-to-Partnering-with-Us
Parasiticides
Science and Innovation - Animal Health Innovation - Parasiticides
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Western Canada
Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.
Accessible Customer Service Policy
Accessible Customer Service Policy
Quebec
Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim - Value Through Innovation
about-us-global-card
Atrial Fibrillation
Atrial Fibrillation
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Even nature isn’t perfect
Even nature isn’t perfect
Explore our company
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.